User profiles for Cameron J. Turtle
 | Cameron TurtleVerified email at sydney.edu.au Cited by 21838 |
[HTML][HTML] ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising
therapies for hematologic malignancies. Two CAR T products were recently approved …
therapies for hematologic malignancies. Two CAR T products were recently approved …
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes
…, AV Hirayama, F Mastroiani, CJ Turtle… - The Lancet …, 2020 - thelancet.com
The description of a so-called cytokine storm in patients with COVID-19 has prompted
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However, direct …
consideration of anti-cytokine therapies, particularly interleukin-6 antagonists. However, direct …
Immunogenicity of CAR T cells in cancer therapy
Patient-derived T cells genetically reprogrammed to express CD19-specific chimeric
antigen receptors (CARs) have shown remarkable clinical responses and are commercially …
antigen receptors (CARs) have shown remarkable clinical responses and are commercially …
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
BACKGROUND. T cells that have been modified to express a CD19-specific chimeric antigen
receptor (CAR) have antitumor activity in B cell malignancies; however, identification of the …
receptor (CAR) have antitumor activity in B cell malignancies; however, identification of the …
Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells
…, KR Fink, SR Riddell, DG Maloney, CJ Turtle - Cancer discovery, 2017 - AACR
Lymphodepletion chemotherapy followed by infusion of CD19-targeted chimeric antigen
receptor–modified T (CAR-T) cells can be complicated by neurologic adverse events (AE) in …
receptor–modified T (CAR-T) cells can be complicated by neurologic adverse events (AE) in …
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
…, SK Srivastava, A Wacher, CJ Turtle… - Blood, The Journal …, 2009 - ashpublications.org
The adaptive immune system uses several strategies to generate a repertoire of T- and B-cell
antigen receptors with sufficient diversity to recognize the universe of potential pathogens. …
antigen receptors with sufficient diversity to recognize the universe of potential pathogens. …
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells
CD19-specific chimeric antigen receptor (CAR)–modified T cells have antitumor activity in B
cell malignancies, but factors that affect toxicity and efficacy have been difficult to define …
cell malignancies, but factors that affect toxicity and efficacy have been difficult to define …
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
…, SR Riddell, DG Maloney, CJ Turtle - Blood, The Journal …, 2017 - ashpublications.org
Lymphodepletion chemotherapy followed by infusion of CD19-specific chimeric antigen
receptor–modified (CAR) T cells has produced impressive antitumor responses in patients with …
receptor–modified (CAR) T cells has produced impressive antitumor responses in patients with …
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
…, PL Kosasih, T Gogishvili, DG Maloney, CJ Turtle… - Leukemia, 2016 - nature.com
Adoptive T-cell therapy with gene-modified T cells expressing a tumor-reactive T-cell receptor
or chimeric antigen receptor (CAR) is a rapidly growing field of translational medicine and …
or chimeric antigen receptor (CAR) is a rapidly growing field of translational medicine and …
[HTML][HTML] Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor–modified T cells after failure of ibrutinib
Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor–modified
T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had …
T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had …
